Source: Annual Congress 2008 - Infection year in review
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
G. B. Migliori (Tradate, Italy). Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: epidemiology, diagnosis and treatment. Annual Congress 2008 - Infection year in review

Member's Comments

No comment yet.

Related content which might interest you: Laboratory system to detect multidrug-resistant (MDR) and extensively drug-resistant (XDR) mycobacterium tuberculosis strains in clinical practice Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control Year: 2008 Early access to bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis Source: Eur Respir J, 54 (1) 1802208; 10.1183/13993003.02208-2018 Year: 2019 Multidrug-resistant tuberculosis (MDR-TB) Source: Breathe 2010; 6: 283 Year: 2010 Comparative analysis between multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) in HIV(+) patients Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009 Surgical treatment of multidrug-resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003 Extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB): a retrospective comparative study Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 Extensively drug-resistant (XDR) pulmonary tuberculosis in HIV negative cases Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Multidrug resistant tuberculosis (MDR – TB) treatment outcomes in Iran Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004 Treating extensively drug resistant tuberculosis (XDR-TB) in India Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Clinical and operational value of the extensively drug-resistant tuberculosis definition Source: Eur Respir J 2007; 30: 623-626 Year: 2007 Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Transmission of multidrug-resistant and extensively drug-resistant tuberculosis in a metropolitan city Source: Eur Respir J 2013; 41: 901-908 Year: 2013 Treatment possibilities of multi-drug resistant (MDR) tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 525s Year: 2003 Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009–2016 Source: Eur Respir J, 52 (1) 1800070; 10.1183/13993003.00070-2018 Year: 2018 Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005 Treatment outcomes of extensively-drug resistant tuberculosis (XDR-TB) patients in 20 countries Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012 Facilities for treating multidrug-resistant tuberculosis (MDRTB) in Europe Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology Year: 2016 Multidrug- and extensively drug-resistant tuberculosis: an emerging threat Source: Eur Respir Rev 2009; 18: 195-197 Year: 2009